Compare Cytokinetics Inc (CYTK) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard S&P 500 ETF — how do they compare? Cytokinetics Inc trades at $62.61 (market cap $8.62B), while Vanguard S&P 500 ETF trades at $715.13 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 208.8× Cytokinetics Inc's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vanguard S&P 500 ETF for 55 Days on average.
| CYTK | VOO | |
|---|---|---|
Market Cap | $8.62B | $1.80T |
Volume | 2,594,626 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $87.26 | $716.17 |
52-Week Low | $54.76 | $580.93 |
Typical Hold Time | 19 Days | 55 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
VOO trades at $713.62, down slightly by 0.11% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 68.50 suggesting mild overbought conditions. Recent news highlights VOO's role in long-term wealth building through capital growth rather than dividends, with one article positioning it as a recession-resistant holding.
VOO offers diversified exposure to S&P 500 companies with strong institutional backing. Key risks include market volatility from interest rate uncertainty and potential earnings growth slowdown from 35% to 15% in 2027. The ETF remains a core holding for long-term investors despite short interest increasing 46.9% in September.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
